ResMed stock heads into the open after a 0.2% dip
Published on 09/11/2026 at 07:09 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
ResMed stock closed at USD 219.58 on the NYSE on September 10, 2026, slipping 0.2% from the prior close in a relatively calm session. The shares moved between an intraday low of USD 218.15 and a high of USD 221.40, with volume around 814,600 shares, below the recent average per NYSE data referenced by Yahoo Finance. Compared with the broader market, the move left ResMed modestly softer than the Nasdaq Composite, which was roughly flat at the close on September 10, 2026.
September 10, 2026 in numbers
ResMed Inc. (ISIN US7611521078, NYSE: RMD) traded in a fairly tight range on September 10, 2026, with a closing price of USD 219.58 that sat near the middle of the day’s low of USD 218.15 and high of USD 221.40, according to quote data for RMD on Yahoo Finance. The session’s volume of about 814,600 shares was notably below the recent average of roughly 1.5 million shares, indicating more subdued trading activity than earlier in the week. The close left the stock slightly below a recent quote of USD 219.95 cited in an insider-trading report and about 0.2% under that level, keeping ResMed within reach of the upper half of its 52-week trading band per the same data provider.
Insider activity remained a talking point around the name after ResMed’s chairman and chief executive officer Michael Farrell disclosed the sale of roughly USD 1.11 million of company shares on September 8, 2026, in a Form 4 filing described by Investing.com. A separate market wrap noted that ResMed stock had already closed at USD 221.05 on September 9, 2026, down 3.3% as the CEO’s share sale drew investor attention, and cited a subsequent quote near USD 219.52 on September 10, 2026, reinforcing that insider selling remained a visible factor in recent trading, as reported by Ad-hoc-news.
Today’s drivers and upcoming dates
With no major company-specific release scheduled for September 11, 2026 in the immediate earnings calendars consulted, trading in ResMed today is likely to remain sensitive to ongoing discussion of insider activity and broader health-care sector moves rather than a single scheduled catalyst. The recent insider sale described by Investing.com and the follow-up price commentary from Ad-hoc-news remain part of the backdrop as investors head into the open. Looking slightly further ahead, the earnings calendar section of Yahoo Finance referenced by Ad-hoc-news lists October 29, 2026 as the estimated date for the next quarterly earnings release, giving a clear medium-term milestone that many investors will watch for updated revenue and margin trends.
